Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018–2021

We read the article by Zhao et al., in which the prognosis of hematological patients with Pseudomonas aeruginosa bloodstream infections was closely related to the time to effective treatment, with great interest. 1 Zhao Y. Lin Q. Zhang T. Zhen S. Wang J. Jiang E. et al. Pseudomonas aeruginosa bloodstream infection in patients with hematological diseases: clinical outcomes and prediction model of multidrug-resistant infections. J Infect. 2023; 86: 66-117 Abstract Full Text Full Text PDF Scopus (3) Google Scholar A recent study from the Antimicrobial Testing Leadership and Surveillance program (ATLAS) program in 2015–2019 concluded that the resistance patterns and the associated genes varied significantly among different countries, and India had the highest rates of carbapenem resistance in P. aeruginosa isolates in the Asia-Pacific region. 2 Lee Y.L. Ko W.C. Hsueh P.R. Geographic patterns of carbapenem-resistant Pseudomonas aeruginosa in the Asia-Pacific region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) Program, 2015–2019. Antimicrob Agents Chemother. 2022; 66e0200021 Crossref Scopus (13) Google Scholar